Abstract: Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.

Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract: Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.

Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Abstract: An electronic device includes an image reading section, a marker detection section, and a processing section. The marker detection section analyzes image data and detects a first marker portion indicated in the image data and a second marker portion indicated in the image data in a mode different from a mode of the first marker, and also extracts texts indicated in the first marker portion and the second marker portion. The processing section performs processing of transmitting the image data where the text indicated in the first marker portion is defined as a file name of the image data and the text indicated in the second marker portion is defined as a transmission address to which the image data is transmitted.

Abstract: An electronic device includes an image reading section, a marker detection section, and a processing section. The marker detection section analyzes image data and detects a first marker portion indicated in the image data and a second marker portion indicated in the image data in a mode different from a mode of the first marker, and also extracts texts indicated in the first marker portion and the second marker portion. The processing section performs processing of transmitting the image data where the text indicated in the first marker portion is defined as a file name of the image data and the text indicated in the second marker portion is defined as a transmission address to which the image data is transmitted.

Abstract: Provided are: an acquisition section that acquires image data; a detection section that detects a marker portion indicated in the image data; a communication section that performs communication with either one or a plurality of external servers including at least one of a plurality of dictionary functions; a processing section that (i) specifies, from the dictionary functions, a dictionary function in accordance with a type of the marker portion, and (ii) causes the communication section to transmit, to the external server including the specified dictionary function, an instruction to search for a text indicated by the marker portion, and for information related to the text, by using the dictionary function; and a generation section that generates a glossary including the received information related to the text upon reception of the information related to the text as a search result from the external server by the communication section.

Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.

Abstract: Provided are: an acquisition section that acquires image data; a detection section that detects a marker portion indicated in the image data; a communication section that performs communication with either one or a plurality of external servers including at least one of a plurality of dictionary functions; a processing section that (i) specifies, from the dictionary functions, a dictionary function in accordance with a type of the marker portion, and (ii) causes the communication section to transmit, to the external server including the specified dictionary function, an instruction to search for a text indicated by the marker portion, and for information related to the text, by using the dictionary function; and a generation section that generates a glossary including the received information related to the text upon reception of the information related to the text as a search result from the external server by the communication section.

Abstract: A learning support device includes a storage portion which stores the images of model characters, an image reading portion which reads a practice sheet to generate image data, a determination portion which extracts, as an image of a determination target character, an image of a handwritten character present within the image data on the practice sheet, which acquires, from the storage portion, the image of the model character and which compares the image of the model character with the image of the determination target character so as to perform a pass/fail determination, a generation portion which generates image data on a report that includes result information indicating the result of the pass/fail determination and an output portion which outputs the report including the result information.

Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.

Abstract: An image processing apparatus includes an acquisition section, a marker detecting section, a text extracting section, and a markup language processing section. The marker detecting section detects, based on the image data acquired by the acquisition section, a marker assigned to an original document. The text extracting section analyzes the image data to recognize and extract a text in the original document. The markup language processing section generates markup data in which the text in the image data has the same display color as the marker.

Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.

Abstract: A printing management system includes an image forming apparatus and a server apparatus. The image forming apparatus includes an acceptance section, a printing section, a reading section, a first transmission section, a first reception section, and a determination section. The determination section, when the acceptance section accepts a print request or a read request, determines whether or not template paper is to be printed, on the basis of the total number of printed copies and the total number of read copies received by the first reception section. The server apparatus includes a second reception section, a storage section, a counting section, and a second transmission section. The counting section obtains the total number of printed copies on the basis of the number of printed copies and user identification information, obtains the total number of read copies on the basis of the number of read copies and the user identification information.